Latest News

• AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference CallMarch 9, 2010, BOTHELL, WA
• AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular DystrophyFebruary 15, 2010, BOTHELL, WA
• AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular DystrophyFebruary 5, 2010, BOTHELL, WA
• AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of ToxicologyFebruary 4, 2010, BOTHELL, WA
• TMTI Accomplishments Have Advanced the Nation's Ability to Successfully Counter an Emerging BiothreatJanuary 15, 2010, BOTHELL, WA
• Systemic Treatment with AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy PatientsDecember 22, 2009, BOTHELL, WA
• AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference November 19, 2009, BOTHELL, WA
• AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry DayNovember 18, 2009, BOTHELL, WA
• AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate HighlightsNovember 9, 2009, BOTHELL, WA
• AVI BioPharma Announces Third Quarter 2009 Financial Results Conference CallNovember 2, 2009, BOTHELL, WA

News Archives

• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002